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stromal tumours
César Serrano1,2,3, Adrián Mariño-Enríquez1, Derrick L. Tao1, Julia Ketzer4, Grant Eilers1, Meijun Zhu1, Channing Yu2,5,11,
Aristotle M. Mannan5, Brian P. Rubin6, George D. Demetri2,7, Chandrajit P. Raut2,8, Ajia Presnell9, Arin McKinley9, Michael C. Heinrich 9,
Jeffrey T. Czaplinski2, Ewa Sicinska10, Sebastian Bauer4, Suzanne George2 and Jonathan A. Fletcher1,2
BACKGROUND: Most patients with KIT-mutant gastrointestinal stromal tumours (GISTs) benefit from imatinib, but treatment
resistance results from outgrowth of heterogeneous subclones with KIT secondary mutations. Once resistance emerges, targeting
KIT with tyrosine kinase inhibitors (TKIs) sunitinib and regorafenib provides clinical benefit, albeit of limited duration.
METHODS: We systematically explored GIST resistance mechanisms to KIT-inhibitor TKIs that are either approved or under
investigation in clinical trials: the studies draw upon GIST models and clinical trial correlative science. We subsequently modelled
in vitro a rapid TKI alternation approach against subclonal heterogeneity.
RESULTS: Each of the KIT-inhibitor TKIs targets effectively only a subset of KIT secondary mutations in GIST. Regorafenib and
sunitinib have complementary activity in that regorafenib primarily inhibits imatinib-resistance mutations in the activation loop,
whereas sunitinib inhibits imatinib-resistance mutations in the ATP-binding pocket. We find that rapid alternation of sunitinib and
regorafenib suppresses growth of polyclonal imatinib-resistant GIST more effectively than either agent as monotherapy.
CONCLUSIONS: Our data highlight that heterogeneity of KIT secondary mutations is the main mechanism of tumour progression to
KIT inhibitors in imatinib-resistant GIST patients. Therapeutic combinations of TKIs with complementary activity against resistant
mutations may be useful to suppress growth of polyclonal imatinib-resistance in GIST.
British Journal of Cancer (2019) 120:612–620; https://doi.org/10.1038/s41416-019-0389-6
BACKGROUND
Gastrointestinal stromal tumour (GIST) is a mesenchymal tumour
of the gastrointestinal tract and the most common subtype of
human sarcoma.1,2 KIT or PDGFRA receptor tyrosine kinase gain-
of-function mutations are crucial initiating oncogenic events in
90% of GISTs,3,4 resulting in oncogenic addiction. Therefore,
abolition of KIT or PDGFRA signalling with tyrosine
kinase inhibitors (TKIs) profoundly impairs GIST cell viability and
growth.5,6
First-line imatinib mesylate (Gleevec, Novartis Oncology, Basel,
Switzerland) inhibits activity of mutant KIT and PDGFRA, and
substantially improves survival in most GIST patients.6,7 However,
most patients with initial clinical benefit from imatinib eventually
progress, typically in 20–24 months.6,7 Oncogenically-activated KIT
continues to be the key driver of GIST proliferation and survival
after imatinib failure in up to 90% of the patients, due to
reactivation of KIT signalling by tumour subclones with hetero-
geneous secondary KIT mutations.8–11 These KIT secondary
mutations cluster in two regions of the kinase domain: the ATP-
binding pocket (encoded by exons 13 and 14) and the activation
loop (encoded by exons 17 and 18).
Current drug development strategies for imatinib-resistant GIST
exploit continued KIT-dependency by seeking TKIs which inhibit a
broader spectrum of KIT secondary mutations. These efforts led to
regulatory approval of sunitinib (Sutent, Pfizer Inc.; New York, USA)
and regorafenib (Stivarga, Bayer HealthCare Pharmaceuticals Inc.,
Montville, NJ, USA) as second- and third-line therapies, respec-
tively, for patients with advanced GIST.12–15 Other multikinase
inhibitors are currently in phase I to phase III clinical studies.16,17
Because sunitinib and regorafenib are broadly-active multi-kinase
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inhibitors, they are associated with more toxicities than imatinib in
most GIST patients. Further, after clinical progression of advanced
GIST on imatinib, the clinical benefit of sunitinib and regorafenib is
limited, with median time to progression of 6 months or less.16,17
Our previous studies have shown that some but not all imatinib-
resistant KIT-mutations respond to sunitinib. Specifically, in vitro
and clinical studies demonstrated that sunitinib is active against
imatinib-resistant GIST subclones with KIT ATP-binding pocket
V654A secondary mutations, but inactive against subclones with
KIT activation loop mutations.12,18 Thus, clinical progression on
sunitinib occurs after a median time of 6 months,14 mainly due to
the emergence of cross-resistant KIT-dependent subclones.8–11
Likewise, polyclonal heterogeneity of KIT-driven, imatinib-resistant
subclones might also lead to the modest benefit observed with
regorafenib and other available TKIs as single-agent therapies.
In this study we further explored the relationship between
secondary KIT kinase mutations and the activity of third-line
regorafenib and other TKIs with KIT inhibitory activity being
investigated in GIST clinical trials. To this end, we determined the
activity of multiple TKIs against imatinib-sensitive and imatinib-
resistant KIT mutations in clinically representative, patient-derived
GIST models. We found that regorafenib, as well as all small
molecule KIT-inhibitor monotherapies, have a drug-specific
activity profile against a subset of the KIT secondary mutational
spectrum. Interestingly, some of these TKIs, including second- and
third-line sunitinib and regorafenib, have complementary activity
against resistant clones, and therefore we further undertook an
in vitro proof-of-concept combination strategy based on rapid TKI




CHO cells were from the American Type Culture Collection
(Manassus, VA, USA) and were transfected with KIT-mutant cDNA
constructs as previously described9 and treated with imatinib,
sunitinib or regorafenib. GIST cells used in these studies were
derived from human GIST metastases and have been published
previously19 with the exception of GIST226, which is a novel KIT-
negative GIST line that contains (but does not express) homo-
zygous primary KIT exon 11 in-frame deletion (P551-W557) and
homozygous KIT exon 17 Y823D mutations. All lines were
credentialed by Sanger sequencing evaluations of known muta-
tions, at baseline and every 3 months during the study. All cultures
were shown to be mycoplasma-free.
Protein blotting
Whole cell lysates were prepared as described previously,20 and
protein concentrations were determined using the Bio-Rad
protein assay (Bio-Rad, Hercules, CA, USA). KIT immunoprecipita-
tions, in the CHO cell assays, were as described previously.9
Electrophoresis, immunoblotting, and chemiluminescence detec-
tion were as described previously.21 Primary antibodies to
phospho-KIT Y721 (#3391), phospho-KIT Y703 (#3073), phospho-
AKT S473 (#9271), AKT (#9272), phospho-RB1 S795 (#9301) and
RB1 (#9309) were from Cell Signaling Technology (Danvers, MA,
USA); to KIT (#A4502) were from Dako (Carpinteria, CA, USA); to
actin (#A4700) were from Sigma (San Luis, MI, USA); and to Cyclin
A (clone 6E6) were from Leica Byosistems (Wetzlar, Germany).
Immunohistochemistry
Immunohistochemical staining for Ki-67 was performed against
cell cultures on chamber slides with an antibody (#0505) from
Immunotech (Marseille, France) at dilution of 1:200. Then the
slides were incubated with a biotin-conjugated secondary anti-
body and stained using the Ventana (Tucson, AZ, USA) DAB
detection kit with counterstaining by haematoxylin.
Reagents
Ponatinib and regorafenib were from Selleck Chemicals (Houston,
TX, USA). Dovitinib, dasatinib, imatinib, masitinib, nilotinib, suniti-
nib, and sorafenib were from LC Laboratories (Woburn, MA, USA).
Cell viability studies
The sulforhodamine B (SRB) assay was used according to the
method of Skehan.22 Cells were plated in 96-well flat-bottomed
plates. After 24 h culture medium was replaced with fresh medium
(with or without drugs) in triplicate cultures. At the end of drug
exposure (72 h), cells were fixed for 1 h and stained with 0.4% SRB
(Sigma Aldrich, St. Louis, MO USA) and the optical density was
detected at 560 nm. Each experiment was repeated three times.
Clinical correlative studies
Tumour specimens for genotype analyses were obtained from
patients enrolled on a phase II clinical trial of regorafenib in GIST.23
Briefly, patients were adults who had histologically confirmed
metastatic and/or unresectable GIST with progression or intoler-
ance to imatinib and prior failure to sunitinib. Tumour tissue was
analysed in patients receiving regorafenib 160mg daily 3-weeks
on, 1-week off. Objective response was assessed by computed
tomography (CT) in genotyped patients at baseline and at the end
of every even-numbered cycle. Disease status was assessed using
Response Evaluation Criteria in Solid Tumours (RECIST) as
complete response (CR), partial response (PR), stable disease
(SD), or progressive disease (PD).24 Metabolic response was
assessed by serial [18F]fluoro-2-deoxy-D-glucose positron emission
tomography (FDG-PET) scans were done in a fasting state 1 h
following i.v. administration of FDG (15–20mCi) at baseline, at the
end of cycle 1 and cycle 4 dosing.
GIST xenograft studies
A patient-derived xenograft (PDX) model, PG48, was developed
from the regorafenib-resistant GIST patient #1. This PDX has a
homozygous KIT exon 11 primary mutation (V559D) and a
homozygous KIT exon 13 secondary ATP-binding pocket mutation
(V654A). All in vivo work was conducted under appropriate
Institutional Animal Care and Use-Committee-approved protocols.
Six- to 8-week-old female adult athymic nude mice (NMRI nu/nu)
were obtained from Charles River Laboratories (Wilmington, MA,
USA) and housed under specific pathogen-free conditions. Tissue
fragments of PG48 were serially passaged in donor mice injected
subcutaneously in each rear flank. In all studies, vehicle control or
study drugs were administered orally once daily. Solutions and
drug doses were as follows: sterile water, and 100mg/kg/day for
Imatinib; citrate buffered (pH 3.5), and 40mg/kg/day for
sunitinib25; PEG400/125 mM aqueous methanesulphonic acid
(80/20), and 30mg/kg/day for regorafenib.15 The experiment
was stopped after 3 days of treatment, mice were sacrificed, and
tumours were harvested for protein analysis.
Drug-withdrawal studies
GIST cell lines were cultured in serum-containing media in the
presence of DMSO, imatinib, sunitinib or regorafenib at the
indicated concentrations. Drugs were withdrawn and washed out,
and cells were grown in regular media. Study time-points were as
follows: day 0 (on drug), and days 1, 3 and 7 after drug withdrawal.
Cultures were performed in 6-well plates to obtain cell lysates to
assess KIT pathway and cell cycle activation, and in Lab-TEK II
chamber slides (Thermo Fisher, Walthman, MA, USA; #154526) to
assess cell proliferation (KI67 immunostaining and mitotic count)
as described above.
Validation of a rapid-alternation schedule in mixed GIST cell
cultures
Human GIST cells with clinically representative KIT mutations
(GIST-T1, GIST430/654 and GIST-T1/820) were stably infected with
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lentiviruses containing specific 24-basepair DNA “barcodes”, as
described previously.26 Equally numbers of each of the three cell
lines were added to create mixed GIST cell cultures. Mixed GIST
cell cultures were treated with sunitinib (200 nM) and regorafenib
(400 nM), as single-agents or in rapid-alternation. Genomic DNA
was isolated using QIAamp DNA Mini Kit (Quiagen, Germantown,
MD, USA) on day 0 (baseline), 7, 14, 21 and 28, and analysed using
PRISM technology.27 PRISM allows assessment of relative cell
viability in mixtures of cell lines via the quantification of unique
DNA barcodes incorporated into individual cell lines. Results are
shown as percentage of cell numbers relative to untreated. Two-
sided unpaired t-test is used for cell number comparisons
between treatment conditions.
RESULTS
Each of nine small molecule KIT-inhibitors has activity against only
a subset of common imatinib-resistance oncogenic KIT mutations
Nine TKIs that have either been approved or are under clinical
investigation as KIT-inhibitors for GIST were evaluated by viability
assays in GIST cell lines representing four biologic categories: 1)
imatinib-sensitive with KIT primary mutations; 2) imatinib-resistant
due to KIT ATP-binding pocket secondary mutations; 3) imatinib-
resistant due to KIT activation loop secondary mutations; and 4)
imatinib-resistant with acquired loss of KIT oncoprotein expression
(acquired KIT-negative). Each of these TKIs was active against
GIST cells with KIT primary mutations in exon 11 (GIST-T1 and
GIST430) but failed to inhibit the full range of secondary imatinib-
resistance mutations (Table 1). Imatinib and masitinib were
ineffective against all of the common KIT secondary mutations.
The other seven TKIs had activity against GIST cells with some but
not all imatinib-resistance mutations (Table 1). Sunitinib and
dovitinib inhibited viability of GIST cells dependent on the KIT
exon 13 V654A secondary mutation, with IC50 values lower than
500 nM (IC50 45 nM and 250 nM, respectively). The ponatinib IC50
for GIST with KIT V654A was 100 nM, but this exceeds the clinically
relevant concentration (<28 nM) for this drug,28 confirming
previous evidence that ponatinib is not sufficiently active against
this common resistance mutation.19 A broader group of TKIs
(sunitinib, regorafenib, sorafenib, ponatinib and dovitinib) inhib-
ited GIST cells dependent on the “gatekeeper” KIT exon 14 T670I
mutation (IC50 5–200 nM). Sunitinib and dovitinib lacked activity
against secondary mutations in the KIT activation loop (KIT exons
17 and 18), in contrast to regorafenib, sorafenib, nilotinib,
ponatinib and dasatinib, which inhibited viability of GIST cells
dependent on some or all of the activation-loop mutants (Table 1).
No substantial TKI effects were observed in KIT-independent GIST
cell lines GIST48B and GIST226 (Table 1), which underscores that
TKI-activity is typically mediated by blocking KIT signalling in
imatinib-resistant GIST. These observations are consistent with
previously reported clinicopathologic evidence that short-duration
clinical responses in KIT-mutant GIST, after development of
imatinib-resistance, result from outgrowth of cross-resistant GIST
subpopulations with both ATP-binding pocket and activation loop
KIT secondary mutations.8–11
Regorafenib activity in GIST is mediated through KIT oncogenic
signalling inhibition and displays a complementary activity profile
with sunitinib against KIT secondary mutations
Evaluations of the three FDA- and EMA-approved drugs for the
treatment of GIST, imatinib, sunitinib and regorafenib, demon-
strated that each drug inhibited oncogenic KIT and downstream
AKT phosphorylation in a dose-dependent manner in GIST cells
containing only KIT primary exon 11 mutations (GIST-T1, GIST430
and GIST882) without KIT secondary mutations (Fig. 1a). By
contrast, in GIST cells with KIT exon 11 primary mutations
coupled to common secondary KIT imatinib-resistance muta-
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sunitinib and regorafenib. Specifically, GIST cells in which KIT
exon 11 primary mutation was coupled to a secondary mutation
in exon 13 V654A mutation were inhibited only by sunitinib,
whereas GIST cells with KIT exon 11 primary mutation coupled to
an exon 14 T670I gatekeeper mutation were inhibited by
sunitinib and regorafenib (Fig. 1b), and GIST cells with KIT exon
11 primary mutation coupled to exon 17 D816E or D820A or
exon 18 A829P activation loop mutations were inhibited by
regorafenib only (Fig. 1c). Neither sunitinib nor regorafenib
inhibited viability or AKT phosphorylation in KIT-negative GIST
cell lines GIST48B and GIST226 (Fig. 1d). Consistent with these
in vitro results in GIST cells, evaluations of primary and
secondary KIT mutants transfected in Chinese Hamster Ovarian
(CHO) cells showed that sunitinib was more active than
regorafenib against the KIT exon 13 V654A ATP-binding pocket
mutant, whereas regorafenib was more active than sunitinib
against KIT exon 17 activation loop mutants (Supplementary
Figure 1).
Correlative science studies show suboptimal regorafenib clinical
activity against the common KIT V654A imatinib-resistance
mutation in GIST
Imaging studies and tissue biopsies were obtained from two
GIST patients treated with regorafenib in a phase II clinical
trial.23 These two patients received standard regorafenib dosing
(160 mg, 3-weeks on, 1-week off) throughout the study. After
9 months on therapy, patient #1 developed a metabolically
active mediastinal lesion (Fig. 2a), which was resected.
Histologically, the lesion lacked treatment effect, and genotype
analysis revealed a primary KIT exon 11 mutation and a
secondary KIT exon 13 V654A mutation. The patient resumed
regorafenib treatment and, after 12 months, developed further
resistant disease in the abdomen; analysis of this lesion again
revealed a KIT exon 13 V654A mutation, in addition to the
primary KIT exon 11 mutation. By contrast, patient #2 had pre-
treatment biopsy demonstrating primary KIT exon 11 and
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Fig. 1 KIT oncoproteins in GIST are differentially inhibited by sunitinib and regorafenib. Immunoblotting evaluations of phospho-KIT and
downstream phospho-AKT were performed in GISTs belonging to four clinical-genotypic categories: (a) imatinib-sensitive GISTs contained
only KIT primary mutations; (b) imatinib-resistant GISTs with ATP-binding pocket KIT secondary mutations; (c) imatinib-resistant GISTs with
activation loop KIT secondary mutations; (d) KIT-negative GISTs. This figure also provides quantifications, relative to the DMSO-only controls
(normalised to 1.0), of the (a–c) phosphoKIT and phosphoAKT responses in KIT-dependent GISTs
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metabolic response and partial response by RECIST after 4 cycles
of treatment with regorafenib (Fig. 2b). Complete metabolic
response in this lesion was seen 18 days after treatment
initiation.
We extended these in vitro and clinical data in a xenograft
model derived from a regorafenib-resistant GIST, which contained
KIT exon 11 and KIT exon 13 (V654A) mutations. In this model, KIT
phosphorylation was inhibited substantially (80%) by sunitinib
treatment, but not (8%) by regorafenib treatment (Supplementary
Figure 2).
Proof-of-concept of rapid TKI alternation treatment in
heterogeneous GIST co-cultures
Because the above-mentioned in vitro, in vivo and clinical data
indicated complementary activity of sunitinib and regorafenib
against the most common KIT imatinib-resistance secondary
mutations (Fig. 3), we hypothesised that combined treatment
with sunitinib and regorafenib might suppress a broad range of
resistant subclones in GIST patients progressing on imatinib.
However, sunitinib and regorafenib share overlapping toxic
effects, and concurrent treatment with these drugs would likely
a b
Fig. 2 Clinical evidence that GIST imatinib-resistant KIT mutations have differential responsiveness to regorafenib. Two GIST patients
were treated at the standard regorafenib dose (160 mg/d, 3 weeks on, 1 week off ) and imaging and tissue specimens were available.
a Patent #1 developed a new site of metastatic disease after 12 cycles of treatment, which was FDG-avid in the PET/CT. Resection and
sequencing of this progressing lesion showed a V654A KIT ATP-binding pocket secondary mutation. b Patient #2 had a 4.5 × 3.2 cm
metastatic lesion in the abdominal wall that was biopsied and sequenced prior to regorafenib therapy. A KIT activation-loop imatinib-
resistance mutation in exon 17 (D820Y) was found. After 5.5 months on regorafenib treatment, tumour size diminished to 3.0 × 1.6 cm and






























Fig. 3 Schematic view of representative KIT secondary mutations after imatinib failure, frequency according to prior reports,8,9,11,18,36,37 and
predicted activity profile of the three drugs currently approved for the treatment of GIST based on our studies. Green and red denotes
sensitive and resistant, respectively, to imatinib (IM), sunitinib (SU) and regorafenib (RE). Regorafenib square for D816 is both red and green
due to the presence of resistant amino acid changes (i.e., D816V is highly resistant to all TKIs)
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exacerbate each drug’s toxicities. Therefore, we modelled a
concept for rapid alternation of these drugs, aiming to inhibit
growth of heterogeneous cross-resistant subclones, while mini-
mising toxicity. Because this alternating dosing could permit
regrowth of targeted subclones when the relevant drug for those
subclones is withheld, we evaluated a rational time-frame for drug
withdrawal, to establish a treatment schedule that minimises GIST
regrowth during alternating drug withdrawal periods.
Drug withdrawal studies were performed using sunitinib-
sensitive GIST430/654 (Table 1) and regorafenib-sensitive
GIST48/820,19 after treatment with sunitinib and regorafenib,
respectively. In these studies, the drugs were withdrawn after
inhibition of KIT phosphorylation and cell proliferation was
achieved. Partial re-activation of KIT phosphorylation and down-
stream AKT phosphorylation was observed 24 h after drug
withdrawal in both cell lines. Cell cycle re-activation, as evidenced
by upregulation of phospho-RB1, cyclin A, and Ki-67, occurred
3-to- 7 days after drug withdrawal (Fig. 4a). Complete restoration
of Ki-67 expression and mitotic activity occurred 7 days after drug
withdrawal (Fig. 4b and c). These effects on KIT signalling and cell
cycle re-activation were dose-dependent. These observations
define a time-frame for TKI alternation in which substantial
recovery of in vitro cell proliferation occurs within 7 days, whereas
minimal, if any, recovery is seen within 3 days after TKI withdrawal.
To test the effects of drug withdrawal and rapid drug
alternation on heterogeneous GIST populations, we established
polyclonal co-cultures of GIST cell lines containing clinically
relevant KIT mutations: exon 11 mutation alone (GIST-T1), exon
11 primary mutation in cis with exon 13 secondary mutation
(GIST430/654), and exon 11 primary mutation in cis with exon
17 secondary mutation (GIST-T1/820), modelling the polyclonal
imatinib-resistance heterogeneity observed in many GIST patients.
Each cell line was labelled with a unique DNA barcode to allow
quantification of the relative amount of each line in the co-culture
RE 100 nM RE 500 nM
0 1 3 7 0 1 3 70 1 3 7 0 1 3 7
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Fig. 4 Restoration of GIST oncogenic signalling pathways and proliferation after TKI withdrawal. a Immunoblotting evaluations show
reactivation of KIT and AKT, as assessed by phospho-KIT and phospho-AKT, and show reactivation of the cell cycle, as assessed by phospho-
RB1 and Cyclin A. b Ki-67 staining shows recovery of proliferation after drug withdrawal. c, Mitotic counts (per 5mm2) show recovery of
proliferation after drug withdrawal
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using the PRISM method.27 Co-cultures were established with
equal representation of the three cell lines and expanded for
4 weeks under the following conditions: (1) untreated; (2)
continuous sunitinib; (3) continuous regorafenib; or (4) rapid
alternation of sunitinib and regorafenib (sunitinib 3 days, alter-
nating with regorafenib 4 days). The sunitinib and regorafenib
alternation was more effective than either drug alone with respect
to inhibiting growth of these polyclonal populations and
preventing emergence of a single dominant clone (Fig. 5a). In
the GIST polyclonal co-cultures receiving monotherapies, we
observed overrepresentation of the known cross-resistant clone.
Although imatinib-resistant co-cultures were not eradicated, total
numbers of both GIST-T1/820 and GIST430/654 were reduced in
the co-cultures treated with rapid alternating combination of
sunitinib and regorafenib (Fig. 5b).
DISCUSSION
The crucial oncogenic events in most GISTs are gain-of-function
KIT mutations, which cause KIT tyrosine kinase constitutive
activation and resultant constitutive signalling through growth-
promoting pathways, including PI3K/AKT/mTOR and RAS/RAF/
MEK.29 These primary KIT mutations typically involve KIT exons 9
or 11, corresponding to extracellular dimerization domains and
intracellular inhibitory juxtamembrane domains, respectively. The
imatinib-resistance mechanisms responsible for clinical progres-
sion in KIT-mutant GISTs commonly involve emergence of
polyclonal subpopulations with secondary KIT kinase domain
mutations.8–11 KIT-independent mechanisms leading to imatinib-
progression in KIT-mutant GIST have been reported but are
infrequent and yet to be thoroughly studied.17,30 Therefore, KIT
inhibitory strategies after failure of imatinib remain useful because
most imatinib-resistant GISTs are still dependent upon KIT
signalling for survival and proliferation. This has been evidenced
by GIST antiproliferative responses in both preclinical models and
patients, after treatment of imatinib-resistant GISTs by various KIT-
inhibitor strategies, including RNA interference,9 alternative KIT
kinase inhibitors such as sunitinib,12,18 or HSP90 inhibitors.31
However, the frequently polyclonal nature of GIST imatinib-
resistance constitutes a clinical challenge and explains why
sunitinib, the current second-line standard-of-care, generally has
only modest efficacy in GIST patients.14 Conceivably, this
heterogeneous nature of KIT secondary mutations also limits the
clinical benefit of subsequent lines of treatment, including third-
line regorafenib13 and other TKIs under investigation, such that
median time to progression is in the same range as that with
sunitinib.16,17
We and others have previously demonstrated that sunitinib
clinical activity for most GISTs is determined by the primary and
secondary KIT mutations in those tumours.12,18 In the present
study, we provide the first evidence of regorafenib spectrum of
inhibition of imatinib-resistant KIT mutations. We profiled
regorafenib activity against a panel of GIST cell lines containing
the common types of KIT imatinib-resistance secondary muta-
tions in GIST, involving either the KIT ATP-binding pocket or
activation loop. Regorafenib, like imatinib and sunitinib, had
compelling activity against GIST models dependent only on KIT
exon 11 primary mutations, i.e. lacking imatinib-resistant
secondary KIT mutations. In addition, regorafenib inhibited KIT
kinase activation loop secondary imatinib-resistance mutations,
which are known to be sunitinib resistant.12,18 The evidence for
regorafenib activity against KIT secondary activation loop
mutations included preclinical modelling of drug effects on cell
proliferation, KIT phosphorylation, and KIT-pathway phosphor-
ylation. Further, we document regorafenib clinical response in a
patient whose GIST had a KIT activation loop imatinib-resistance
mutation (Fig. 2b), supporting evidence we reported pre-
viously.23 Nonetheless, KIT activation loop secondary mutations
are heterogeneous and the present study demonstrates variable
regorafenib activity depending on the exact activation loop
amino acid alteration. For example, regorafenib was more active
against KIT exon 17 D816E mutation than D816H. Other KIT
oncogenic mutations, including an exon 13 K642E primary
mutation, and the exon 14 T670I “gatekeeper” secondary
mutation, were inhibited effectively by both sunitinib and
regorafenib.32,33 Very similar GIST inhibition profiles were
demonstrated for regorafenib and the structurally-related
compound, sorafenib, demonstrating the reproducibility of
the models.
Regorafenib had only modest activity against the KIT exon 13
V654A secondary mutation, which modifies a residue in the ATP-
binding pocket of the kinase and is the most common secondary
imatinib-resistance mutation in GIST patients following primary
treatment with imatinib.18 In the present study, a patient
progressed twice on a standard regorafenib dose/schedule, and
on each occasion the regorafenib-resistance resulted from KIT
V654A secondary mutation. Likewise, in preclinical studies, we
demonstrated modest inhibition of KIT V654A phosphorylation
only at high doses of regorafenib. Therefore, the evidence to date
indicates that regorafenib does not inhibit effectively the KIT
V654A imatinib-resistance mutation in GIST. By contrast, KIT V654A
is inhibited effectively by sunitinib, as shown in our present
evaluations and in previously published preclinical and clinical
studies.12,18

















































Fig. 5 Suppression of polyclonal imatinib-resistant populations by sunitinib and regorafenib rapid alternation. PRISM analysis of barcoded cell
lines was used to assess mixed GIST cultures treated with single-agent sunitinib, single-agent regorafenib, or rapid alternation (3 days of
sunitinib alternating with 4 days of regorafenib). a Cell numbers were lowest in the rapid alternation arm, at all time-points. b Population
profiling at day 28 demonstrated partial suppression of ATP-binding-pocket (V654A) and activation loop (D820A) imatinib-resistant GIST cells
by the rapid alternation approach
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Our cell viability studies using 9 different TKIs, either approved
or under clinical investigation in GIST, underscore that each of the
targeted KIT-inhibitor small molecule drugs included in this
analysis is active against only a subset of the common imatinib-
resistance secondary KIT mutations. As discussed above, these
limitations have been established in previous studies for
sunitinib,12,18 and are now reported, herein, for regorafenib.
Likewise, our current studies confirm that ponatinib inhibits some
but not all common imatinib-resistance secondary KIT mutations,
with the common KIT exon 13 V654A mutation being a particular
challenge.19 Although the drug screens show differential activity
for each of the TKIs against various imatinib-resistance KIT
mutations, the in vitro IC50 values do not permit precise prediction
of clinical activity, particularly in absence of correlative studies
from GIST biopsies and/or cfDNA in patients receiving these
agents. Overall, regorafenib and sorafenib had comparable activity
in vitro. Although sorafenib IC50 for KIT exon 13 V654A mutation
appears to be lower compared to regorafenib (800 nM vs. 2000
nM), we do not expect meaningful clinical differences for these
two drugs. Masitinib activity fully overlaps with imatinib, showing
a >10–100-fold gap between IC50 in imatinib-sensitive vs.
imatinib-resistant mutants. Nilotinib and dasatinib have similar
profiles, with activity in imatinib-sensitive models and potential
activity against activation-loop mutants, which agrees with
previous reports.34,35 However, and in the light of published
clinical data in imatinib-resistant disease, it is unlikely that nilotinib
and dasatinib activity against KIT secondary mutations in the
activation loop is comparable to that of regorafenib or ponati-
nib.16,17 Finally, dovitinib activity appeared to be comparable to
sunitinib in our studies, with the IC50 for ATP-binding pocket
mutations being 6–30-fold lower than those for mutations in the
activation-loop. All studies in KIT-independent cell lines confirm
that the activity of these TKIs is mediated through KIT oncogenic
signalling inhibition. Together, these studies reinforce that KIT
secondary genotype determines the activity of TKIs with KIT
inhibitory activity in GIST, thereby establishing the molecular basis
for the modest clinical benefit observed with successive lines of
treatment in imatinib-resistant GIST.
The incomplete coverage of imatinib-resistant KIT mutations by
each of these drugs allows cross-resistant GIST subclones to
emerge from a background of heterogeneous GIST cells with
varied KIT secondary mutations, leading to clinical progression
irrespective of the TKI used. Therefore, more effective strategies
for KIT-inhibition are needed in patients with imatinib-resistant
GIST, in order to accomplish longer-lasting clinical benefit. Hence,
we investigated whether rational combinations of KIT inhibitors
could overcome polyclonal resistance after imatinib failure.
Notably, several drugs from our screening displayed complemen-
tary activity profiles with respect to inhibiting either the KIT exon
13 V654A mutation or KIT exon 17 activation loop mutations. Each
of these mutation categories accounts for approximately 40% of
imatinib-resistant subclones in GIST patients (Fig. 3).8–10,18,36,37 In
order to enable translation into a near-term clinical trial in GIST
patients, we focused in these preclinical studies on novel
approaches to administering sunitinib and regorafenib, the two
currently approved drugs for imatinib-resistant GIST. Therapeutic
combinations may augment the magnitude and/or duration of
clinical responses,38,39 and the observed complementary pattern
suggests that a combination of sunitinib and regorafenib could
broaden the spectrum of subclones effectively targeted by
second-line therapy, delaying the emergence of cross-resistant
disease and extending the window of clinical benefit beyond the
4–6 months currently observed with each drug as single-
agent.13,14 However, both drugs share overlapping toxicities and
concurrent treatment would require dose reductions leading to
loss of efficacy in order to minimise adverse events.38,39 Several
studies have shown that continuous dosing is not necessary for
drug efficacy,40–44 and might decrease selective pressure and
minimise positive subclonal selection and subsequent disease
progression:41,42 these observations beg the question as to
whether sequentially alternating sunitinib and regorafenib could
achieve effective doses of both drugs while minimising toxicity.
Thus, we identified and validated in GIST cell models a concept for
rapid-alternation of sunitinib and regorafenib, aiming to maintain
inhibitory pressure on the two major types of imatinib-resistance
KIT mutations that coexist in many GIST patients. These data
provide rationale for a clinical trial in which alternation of sunitinib
for 3 days with regorafenib for 4 days is currently being evaluated
in GIST patients with advanced disease (ClinicalTrials identifier:
NCT02164240).
In summary, this study defines the spectrum of inhibition of
imatinib-resistant KIT mutations by third-line regorafenib and
multiple available TKIs. We find that small molecule KIT-inhibitor
monotherapies have drug-specific activity profiles against only
subsets of the KIT secondary imatinib-resistance mutations, which
constitutes the molecular basis for the modest clinical benefit
observed with successive lines of treatment in imatinib-resistant
GIST. Our studies underscore the need for therapies that suppress
the spectrum of heterogeneous imatinib-resistant subclones that
can arise in a given GIST patient. Leveraging these insights, we
show that rapid alternation of TKIs with complementary activity
can control heterogeneous imatinib-resistance subclones.
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